FORMIT XR 750/MG ER TAB 30/TAB

Indications

Approved Uses

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; may be used as monotherapy or in combination with other antidiabetic agents (including insulin).

Off-Label Uses

PCOS (to improve metabolic parameters/ovulatory function in selected patients), prevention/delay of type 2 diabetes in high-risk prediabetes, mitigation of antipsychotic-associated weight gain (selected cases).

Dosage & Administration

Dosing by Condition

Type 2 diabetes mellitus (ER): Start 500 mg once daily with the evening meal (some patients may start 750 mg once daily depending on product strength/tolerance); increase by 500 mg weekly (or 750 mg every 1-2 weeks) as tolerated; usual effective dose 1500-2000 mg/day; maximum generally 2000 mg/day for most metformin ER products.

Initial Dose

500 mg once daily with the evening meal

Maintenance Dose

1500-2000 mg once daily with the evening meal

Maximum Dose

2000 mg/day (extended-release); 2550 mg/day (immediate-release)

Children's Dosage

Immediate-release metformin is approved for children 10 years and older. The usual starting dose is 500mg twice a day. The maximum daily dose is 2000mg. Extended-release tablets are not approved for use in children.

Dose Adjustment Notes

Titrate gradually (typically in 500 mg increments at ~1-week intervals as tolerated) to reduce GI effects; assess renal function before start and periodically-do not initiate if eGFR 30-45 mL/min/1.73 m², contraindicated if eGFR <30; if eGFR falls <45 during therapy, reassess risk/benefit and consider dose reduction with closer monitoring.

How to Take

Swallow FORMIT XR (metformin ER) tablet whole once daily with the evening meal; do not crush, chew, or split/cut the extended‑release tablet.

Side Effects

Common Side Effects

Diarrhea, nausea, vomiting, abdominal discomfort/pain, flatulence, decreased appetite (anorexia), metallic taste; heartburn/dyspepsia may occur.

Side Effect Frequency

Very common (>10%): gastrointestinal effects (diarrhea, nausea, vomiting, abdominal pain; may include decreased appetite/flatulence). Common (1-10%): taste disturbance (metallic taste). Frequency not known/long-term: vitamin B12 deficiency (reduced absorption). Very rare (<0.01%): lactic acidosis.

Safety & Warnings

Contraindications

Contraindicated in: severe renal impairment (eGFR <30 mL/min/1.73m²), acute or chronic metabolic acidosis (including DKA), and hypersensitivity to metformin; temporary discontinuation is required for certain iodinated contrast procedures in at-risk patients (not a true absolute contraindication).

Warnings & Precautions

Warnings/precautions: lactic acidosis risk (avoid/withhold in hypoxia, dehydration, sepsis, acute illness; assess renal function before and periodically; avoid excessive alcohol; avoid hepatic disease), withhold for iodinated contrast in at-risk patients and around major surgery/acute reduced intake, monitor for vitamin B12 deficiency with long-term therapy, and not indicated for type 1 diabetes or DKA.

Age Restriction

Not recommended/approved for pediatric use (<18 years) for the extended‑release (XR) formulation; if pediatric metformin is used, it is typically the immediate‑release product for ages ≥10 years.

Driving Warning

Safe

Drug Interactions

Drug Interactions

Key interactions: iodinated contrast media (withhold in at-risk patients), alcohol (↑ lactic acidosis risk), carbonic anhydrase inhibitors (e.g., topiramate/acetazolamide; ↑ acidosis risk), cationic drugs that reduce renal tubular secretion/clearance (e.g., cimetidine, ranolazine, dolutegravir; ↑ metformin levels), and agents that affect glycemia (e.g., corticosteroids/diuretics/sympathomimetics may ↑ glucose; insulin/sulfonylureas may ↑ hypoglycemia risk).

Interaction Severity

MAJOR: Iodinated contrast media (temporarily withhold metformin in at-risk patients and around the procedure per eGFR/risk criteria); Excessive alcohol intake (increases lactic acidosis risk). MODERATE: Carbonic anhydrase inhibitors (e.g., topiramate/acetazolamide) (additive acidosis risk); drugs that can impair renal function or hemodynamics (e.g., diuretics/NSAIDs) (increase metformin accumulation risk); hyperglycemia-inducing agents (e.g., corticosteroids) (may reduce glycemic control). MINOR-MODERATE: Cimetidine (can increase metformin exposure via reduced renal tubular secretion).

Food Interaction

Take with food (preferably the evening meal).

Alcohol Interaction

Dangerous

Special Populations

Pregnancy

Consult Doctor

Breastfeeding

Safe

Children

Immediate-release metformin is approved for children 10 years and older. The usual starting dose is 500mg twice a day. The maximum daily dose is 2000mg. Extended-release tablets are not approved for use in children.

Elderly

Start at lower dose and titrate cautiously. Monitor renal function closely due to age-related decline in eGFR. Contraindicated if eGFR <30 mL/min/1.73m². Avoid use in patients ≥80 years unless renal function is confirmed to be normal.

Kidney Impairment

eGFR ≥60: no adjustment; eGFR 45-59: continue/monitor more frequently; eGFR 30-44: do not initiate-if already on, consider dose reduction and close monitoring/benefit-risk; eGFR <30: contraindicated.

Liver Impairment

Avoid use in hepatic impairment (clinical or laboratory evidence of hepatic disease), particularly moderate-to-severe, due to increased lactic acidosis risk; no specific dose adjustment is recommended because use is generally discouraged.

Storage & Patient Advice

Stopping the Medicine

Can be stopped without tapering, but should generally be done under clinician guidance because glycemic control may worsen; stop immediately if lactic acidosis is suspected or if eGFR falls <30 mL/min/1.73m², and withhold as indicated for iodinated contrast/surgery/acute illness.

Overdose

Overdose can cause metformin-associated lactic acidosis (e.g., nausea/vomiting/abdominal pain, hyperventilation, hypothermia, hypotension, bradyarrhythmias, altered mental status); management is emergency care with immediate discontinuation, supportive treatment, and hemodialysis to remove metformin and correct acidosis.

Patient Counseling

Take once daily with the evening meal and swallow whole (do not crush/chew/split); GI upset is common early and usually improves-titration helps; avoid excessive alcohol; tell providers before iodinated-contrast imaging or if dehydrated/seriously ill; seek urgent care for symptoms of lactic acidosis (e.g., unusual muscle pain, severe weakness, trouble breathing, abdominal pain, hypothermia/dizziness); monitor kidneys and periodic vitamin B12; for ER tablets, seeing an “empty shell” in stool can be normal.

Monitoring Requirements

Renal function (eGFR) at baseline and at least annually (more often if eGFR <60 or risk factors); glycemic control (HbA1c about every 3 months until stable then every 3-6 months, plus periodic glucose as clinically indicated); vitamin B12 periodically with long-term use (especially anemia/neuropathy); monitor for GI intolerance and symptoms of lactic acidosis, and assess for conditions predisposing to hypoxia/dehydration.

Pharmacology

Mechanism of Action

Decreases hepatic glucose production (gluconeogenesis), decreases intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake/utilization (mechanistically linked to AMPK activation).

Duration of Effect

Single-dose glucose-lowering effect lasts about 24 hours (extended-release); overall glycemic effect is maintained with continued daily dosing and reaches steady maximal effect over ~1-2 weeks.

Bioavailability

Approximately 50-60% (metformin oral bioavailability; may be lower and slower with extended-release vs immediate-release).

Metabolism

Metformin is not metabolized (including not hepatically metabolized) and is excreted unchanged in the urine via renal tubular secretion.

Excretion

Eliminated unchanged by the kidneys via glomerular filtration and active tubular secretion; the vast majority is excreted in urine (minimal metabolism).

Protein Binding

Negligible; metformin is essentially not bound to plasma proteins.

Product Information

Available Dosage Forms

For this PRODUCT (FORMIT XR 750 mg): Extended-release oral tablet only.

Composition per Dose

Each extended-release tablet: 750 mg metformin hydrochloride

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Diabetes Type

Type 2

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.